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Objective: To examine whether b2-adrenergic agonist-induced hypertrophy of the quadriceps skeletal
muscle can modulate the severity of osteoarthritis (OA) in the rodent meniscectomy (MNX) model.
Methods: Male Lewis rats were subcutaneously administered with 1.5 mg/kg/day clenbuterol hydro-
chloride (n¼ 15) or saline vehicle (n¼ 20) for 14 days. Following pre-treatment, ﬁve animals from each
group were sacriﬁced to assess the immediate effects of clenbuterol. The remaining animals underwent
either invasive knee surgery (clenbuterol pre-treated n¼ 10; saline pre-treated n¼ 10) or a sham control
surgical procedure (saline pre-treated n¼ 5). During disease initiation and progression, weight bearing
was assessed by hindlimb loading. Myosin heavy chain (MHC) protein isoforms were quantiﬁed by silver
stained SDS PAGE. OA severity was graded by assessment of toluidine blue stained step coronal sections
of the total knee joint.
Results: Clenbuterol treatment resulted in an increase in total bodyweight, growth rate and in quadriceps
skeletal muscle mass. Meniscal surgery resulted in the development of OA-like lesions, changes to weight
bearing, and changes in MHC protein expression in the quadriceps. Clenbuterol-induced skeletal muscle
hypertrophy had no effect on either weight bearing or articular pathology following MNX surgery.
Conclusions: Our data reveal that clenbuterol-induced skeletal muscle hypertrophy is unable to mimic the
beneﬁcial clinical effects of increased musculature derived through targeted strength training in humans,
in a rodent model of MNX-induced OA. In addition we observed ﬁbre-type switching to ‘‘slow twitch’’ in
the quadriceps muscle during the induction of OA that warrants further investigation as to its
relationship to joint stability.
 2010 Osteoarthritis Research Society International. Published by Elsevier Ltd.
Open access under the Elsevier OA license. Introduction
It is known that patients with knee osteoarthritis (OA) exhibit
muscle weakness1–9, which is one of the most frequent and earliest
reported symptoms associated with knee OA10. It primarily affects
the quadriceps muscle with little or no evidence of hamstring
weakness4, resulting in a reduced quadriceps to hamstring (Q/H)
ratio11.
Historically, muscle weakness has been considered a secondary
effect in knee OA, resulting from disuse of the affected joint due to
the presence of pain and/or inﬂammation, and therefore hasDaniel P. Tonge, Nutritional
Campus, Sutton Bonington,
nge).
ernational. Published by Elsevier Lreceived little attention with regards to its involvement in the
initiation or progression of OA. However, there is evidence which
suggests that quadriceps weakness may precede the onset of
radiographic evidence of OA and pain2, and be directly involved in
its pathogenesis6. Firstly, quadriceps weakness is reported in those
patients with radiographic signs of knee OA in the absence of pain,
suggesting that the muscle weakness is unlikely to be due to disuse
of a painful joint12. Secondly, quadriceps weakness is noted in
a number of patient groups who are susceptible to developing knee
OA, for example patients who have gait abnormalities resulting in
increased knee loading13, patients with anterior cruciate ligament
(ACL) insufﬁciencies14 and most commonly patients who have
undergone partial meniscectomy (MNX) surgery as a treatment of
medial meniscal tears15. Initially, patients who have undergone
MNX have marked muscle weakness of the ipsilateral limb in the
absence of manifest OA1,16. However, at long-term follow-up,td. Open access under the Elsevier OA license. 
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ratio¼ 10), compared to age and sex matched subjects with no
history of meniscal injury17. In these patient groups, quadriceps
dysfunction is noted prior to any radiographic evidence of OA, again
suggesting that the quadriceps dysfunction reported in knee OA is
unlikely to be solely due to disuse atrophy.
Whether a strong quadriceps muscle can also be a protective
factor in the initiation of OA is perhaps more debatable. A study
examining the incidence of OA at a 5-year follow-up in subjects with
no radiographic evidence of OA at baseline, found that those
subjects who developed OA had weaker quadriceps strength at
baseline18. Conversely, a recent longitudinal study conducted by
Segal, NA and colleagues found that although extensor strength was
reduced with increasing KL grade for tibiofemoral OA at baseline,
neither strength nor normal Q/H ratio was protective against the
development of incident radiographic OA. However, of interest,
increased extensor strengthwas protective against the development
of incident symptomatic whole knee OA albeit this was restricted to
female participants once corrected for knee pain at baseline19.
There is also controversy with regards quadriceps strength and
disease progression in individuals with established knee OA.Whilst
the assessment of patients with established knee OA showed that
a strong quadriceps muscle was protective for cartilage loss at the
lateral compartment of the patellofemoral joint over a 30-month
period in one study20, other studies have found this protective
effect to be limited to females only3 and one study found a detri-
mental effect in malaligned and lax knees21.
Despite this, a number of studies have shown that exercises
aimed at improving quadriceps function have beneﬁcial symp-
tomatic effects in knee OA patients7,8,22–28. For example, the impact
of both high and low resistance training on subjects with knee OA
has been recently investigated,where itwas reported that improved
quadriceps function was associated with a reduction in knee pain
and increased physical ability24. Similarly, strength training (ST) and
balance exercises have also been shown to signiﬁcantly reduce knee
pain and improve physical ability23. To date, only one randomised
controlled trial evaluating the effects of ST programs on the onset
and progression of knee OA has been conducted7. Here, patients
with established knee OA undergoing three sessions of ST per week
had reduced joint space narrowing (JSN) at 30-month follow-up
compared with those patients undertaking range of motion (ROM)
exercises for the same duration. However, patients who were
radiographically normal at baseline exhibited a slightly elevated
incidence of JSN than those undertaking ROM exercises.
Improving skeletal muscle strength and functional performance
through intensive exercise regimes is often inappropriate or contra-
indicated for the majority of OA patients who are elderly, over-
weight, co-morbid andmay be frail. b2-adrenergic agonists, such as
clenbuterol, have potent anabolic effects on skeletal muscle,
inducing increases in lean mass and contractile speed29 similar to
those observed through targeted ST protocols. Therefore, devel-
oping a pharmacological agent that is able to mimic intensive
exercise regimes by improving muscle function in knee OA patients
could provide a plausible route through which to modify the course
of OA during both initiation, and progression2,7,30.
Morphological studies suggest that the muscle dysfunction in
knee OA is due, in part, to atrophy of the muscle ﬁbres. A recent
study noted that all patients assessed with knee OA presented with
atrophy of type II fast-twitch muscle ﬁbres, whilst less than one
third of the patients presented with atrophy of type I slow-twitch
muscle ﬁbres31 as assessed by histochemical staining. This suggests
that quadriceps dysfunction in knee OA is most commonly associ-
ated with atrophy of fast-twitch type II muscle ﬁbres, an observa-
tion supported by previous histochemical studies32. Therefore,
a pharmacological agent that is able to selectively promotehypertrophy of skeletal muscle ﬁbres, thus increasing muscle mass
warrants investigation in an OA context. In this context, clenbuterol
is a synthetic b2-adrenergic agonist, the action of which mimics
adrenaline. Clenbuterol induces muscle hypertrophy via the stim-
ulation of b-adrenoceptors and the subsequent activation of
downstream signalling pathways33. In addition tomarked increases
in skeletal muscle mass in a number of animal models of muscle
wasting34–37, clenbuterol has also been shown to induce slow to
fast ﬁbre transitions in certain muscle groups36,38.
To facilitate the identiﬁcation of such an agent we explored
whether a knownmodulator of muscle mass and muscle ﬁbre type,
the b2-adrenergic agonist, clenbuterol, was able to modify the
severity of joint disease, assessing joint pathology and behavioural
pain, in a MNX-induced rodent model of OA.
Materials and methods
Animals and housing
A total of 35 male Lewis rats (280.4 g 1.7) were housed in
groups of six with free access to food and standard laboratory chow.
Animals were subcutaneously administered the potent b2-adren-
ergic agonist clenbuterol HCl at a dosage of 1.5 mg/kg/day body-
weight (n¼ 15), or saline vehicle (n¼ 20) for a total of 14 days.
Following pre-treatment, ﬁve animals from each group were
sacriﬁced to assess the immediate effects of clenbuterol. The
remaining animals underwent either MNX surgery (clenbuterol
pre-treated n¼ 10; saline pre-treated n¼ 10) or a sham control
surgical procedure (saline pre-treated n¼ 5). Clenbuterol hydro-
chloride (C12H18Cl2N2O$HCl MW 277.2) was sourced from Alexis
pharmaceuticals, UK as a stock powder. A 1.5 mg/ml (w/v) solution
was prepared in sterile physiological saline and aliquots stored at
20C. A fresh aliquot of compound was thawed for each day of
dosing to minimise any degradation over the course of the study.
All sample size calculations were based on variation in surgical
technique, determined from previous studies conducted by the
same surgeon (un-published observations).
Surgical induction of OA (MNX)
All in vivo procedures were carried out in accordance to the UK
Animals (Scientiﬁc Procedures) Act 1986. OA was induced viaMNX
surgery as previously described39. All surgerywas performed under
3.5% Isoﬂuorane inhalational anaesthetics. Rats received a dose of
Cefalexin antibiotic (0.03 ml/100 g Ceporex oral drops) 1 h prior to
and 12, 24, and 36 h post surgery. Animals also received subcuta-
neous analgesia (0.01 ml/100 g Rimadyl, Pﬁzer) on the induction of
anaesthesia and 24 h post surgery. A small incision was made
longitudinally down the medial side of the knee and a cauteriser
was used to work through both the connective tissue and muscle
layers until the medial collateral ligament, anchoring the medial
meniscus to the tibial (TIB) plateau, was identiﬁed. The ligament
was grasped at the TIB end and cut until fully transected. The liga-
mentwas then transected again at the femoral (FEM) end to remove
the portion overlying the meniscus. The meniscus was freed from
the ﬁne connective tissue, allowing a full thickness,medialmeniscal
transection. Sham animals underwent the same surgical procedure
with the omission of medial meniscal transection.
Weight bearing assessment
Weight bearing, as a surrogate of behavioural joint pain, was
measured using an incapacitance meter (Linton Instrumentation,
UK) as described previously40. The operator was blinded to both the
pre-treatment regime and the previous measurements. The
Fig. 1. The effect of subcutaneous administration of clenbuterol (1.5 mg/kg/day) on bodyweight. Male Lewis rats were randomly assigned to one of two experimental groups
receiving daily subcutaneous doses of clenbuterol 1.5 mg/kg/day (n¼ 5) or saline control (n¼ 5). Cumulative weight changes were recorded daily for both clenbuterol (black lines)
and saline treated (grey lines) subjects during a 14-day pre-treatment phase. Data are mean cumulative percentage S.E.M.
Table I
The effect of subcutaneous administration of clenbuterol (1.5 mg/kg/day) on quad-
riceps muscle parameters and MHC protein expression
Parameter Saline Clenbuterol P value
Bodyweight gain (%) 8.37 0.62 11.46 1.94 <0.001
Growth rate (g/day) 1.47 0.10 4.04 0.48 <0.001
Quadriceps mass (g) 4.64 0.21 6.52 0.21 <0.001
Quadriceps mass (% bodyweight) 1.60 0.08 2.01 0.12 0.020
% MHC I 4.84 0.93 4.68 0.92 0.988
% MHC IIa 7.25 2.83 6.29 2.59 0.963
% MHC IIx 22.34 6.50 27.44 2.88 0.631
% MHC IIb 66.55 7.44 62.77 4.21 0.586
Ratio [Iþ IIA]/[IIXþ IIB] 0.13 0.05 0.147 0.05 0.393
Following 14 days of pre-treatment with either clenbuterol (1.5 mg/kg/day) or
saline, protein extracts were prepared from quadriceps specimens and applied to an
SDS PAGE gel. The different MHC protein isoforms were detected by silver staining.
The % myosin data are mean densitometric units expressed as a percentage of the
total MHC signal S.E.M.
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placing the rat in aPerspex tube so thateachhindpawwas restingon
a separate transducer pad. The distribution of bodyweight on each
paw over 3 s was recorded and the average of three separate
measurements taken. Weight readings for the left and right limbs
were taken and thedifference between these calculated andplotted.
Measurements were taken 2 days prior to the start of the study and
then on days 7, 14, 21, 28, and 35. Prior to inclusion in the study, rats
were trained for 1 week to acclimatise them to the new apparatus.
Termination and histopathology
Animals were terminated 21 days post surgery with a rising
concentration of CO2 and death conﬁrmed by cervical dislocation.
Knee joints were obtained for histopathological analysis by making
a full thickness cut 2 cmaboveandbelowthepatella. The jointswere
formalin ﬁxed and decalciﬁed on 10% formic acid prior to processing
by routine vacuum assisted wax inﬁltration. Toluidine blue stained
step-sectionswere evaluated for proteoglycan loss, cartilage erosion
and subchondral cartilage deposits. Sections were subjectively
graded for the most severe changes in cartilage morphology
assessing proteoglycan loss, erosion, proliferation and ﬁbrillation on
any single section and given a score of between 0 and 4 as follows:
0 – pathology not present, 1 – minimal change, small foci, 2 – mild
change, up to 20% affected, 3 –moderate change, up to 50% affected,
4 – severe change, greater than50%affected. Themaximumscore for
the TIB and FEM condyles was 12 respectively, giving a total
obtainable knee score of 24. Proteoglycan loss was generally asso-
ciatedwith a loss of chondrocytes and some chondrocyte clustering.
Proliferation at the joint margin only referred to proliferation at the
edgeof the articular cartilageplateau andnotproliferationdown the
lateral border resulting from the operative procedure. Erosion was
regarded as the frank loss of cartilage matrix not just ‘shrinkage’ or
‘thinning’. All sections were evaluated by an experienced assessor
who was blinded to the animal group in all cases.
Muscle harvest
Whole bilateral quadriceps muscle samples, inclusive of the
rectus femoris, were dissected, weighed and immediately snapfrozen in isopentane cooled with liquid nitrogen. Care was taken to
avoid inclusion of any adipose tissue or additional muscle, most
importantly the tensor fasciae latae and sartorius that are located
within the dissected area.Quadriceps muscle ﬁbre typing
Quadriceps muscle ﬁbres were classiﬁed based on the expres-
sion of myosin heavy chain (MHC) protein. In brief, quadriceps
muscle samples (100 mg) were crushed to a powder under liquid
nitrogen and homogenised in 5 ml of extraction buffer comprising
0.5 M NaCl, 20 mM pyrophosphate, 50 mM Tris, 1 mM ethyl-
enediaminetetraacetic acid (EDTA), and 1 mM dithiothreitol (DTT)
in distilled water, pH 8.0. Following centrifugation at 1000g for
10 min, 500 ml aliquots of the resulting supernatant were added
to an equal volume of 87% glycerol (Fluka). Preparations were
vortexed to ensure thorough mixing and stored at 20C until
required. Following total protein determination4150 ng proteinwas
mixed with loading buffer (4% v/v 87% glycerol, 25 mM 1M
Tris–HCl (pH 6.8), 8% SDS and 20 mg pyronin Y, with 10% v/v beta-
mercaptoethanol added prior to use). The myosin preparations
were separated by sodium dodecyl sulphate polyacrylamide gel
electrophoresis as described by Mizunoya42. Separating gels
Fig. 2. Electrophoretic separation of the various myosin heavy chain protein isoforms in rat skeletal muscle. (A) Silver stained electrophoretic separation demonstrating the
presence of four well-deﬁned bands in the rat quadriceps (Lane 1). Lanes 2 and 3 contain control material from rat diaphragm and soleus respectively with known MHC protein
expression proﬁles. (B) Silver stained electrophoretic separation demonstrating the presence of four well-deﬁned bands in the rat quadriceps in response to various interventions.
Table II
The effects of MNX surgery and pre-treatment with clenbuterol (1.5 mg/kg/day) on
quadriceps muscle parameters and MHC protein expression
Parameter Sham Saline MNX Clenbuterol
MNX
P value
Bodyweight gain (%) 24.03 0.98* 16.92 1.12 20.16 1.11 0.021
Quadriceps mass (g) 5.91 1.19 5.32 1.72 5.60 1.57 0.099
Quadriceps mass
(% bodyweight)
1.69 0.02 1.60 0.05 1.70 0.02 0.154
MHC I 3.55 0.99 7.61 2.15 2.68 0.99 0.081
MHC IIa 7.27 4.24 11.18 1.86 11.69 2.20 0.545
MHC IIx 24.02 2.52 23.54 2.21 22.14 3.16 0.892
MHC IIb 68.10 5.37 60.31 4.07 67.53 3.83 0.359
Ratio [Iþ IIA]/[IIXþ IIB] 0.09 0.04 0.18 0.04 0.15 0.03 0.359
Following 14 days pre-treatment with either the b2-agonist clenbuterol or saline
control, animals were sub-divided into those that underwent MNX surgery (saline
pre-treated n¼ 10; clenbuterol pre-treated n¼ 10) and those that underwent
a sham control surgical procedure (saline pre-treated n¼ 5). Electrophoretic
examination of the quadriceps muscles at 21 days post MNX surgery was performed
to examine changes in the MHC protein expression proﬁle. Protein extracts were
prepared from quadriceps specimens and applied to an SDS PAGE gel and the
different MHC isoforms detected by silver staining. Data are mean densitometric
units expressed as a percentage of the total MHC signal S.E.M.
* Saline MNX signiﬁcantly different from sham procedure P¼<0.05.
D.P. Tonge et al. / Osteoarthritis and Cartilage 18 (2010) 555–562558consisted of 35% v/v glycerol, 8% w/v acrylamide (bis) 49:1 (Sigma),
0.2 M Tris–HCl (pH 8.8), 0.1 M glycine, 0.4% w/v SDS, 0.1% w/v
ammonium persulphate, and 0.05% v/v N,N,N0,N0-tetramethylethy-
lenediamine (TEMED). The stacking gel consisted of 30% v/v
glycerol, 4% acrylamide (bis) 49:1, 70 mM Tris–HCl (pH 6.7), 4 mM
EDTA, 0.4%w/v SDS, 0.1%w/vammoniumpersulphate, and0.05%v/v
TEMED. Gels were prepared the day prior to running and stored
at 4C. The lower running buffer consisted of 0.05 M Tris–HCl,
75 mM glycine, and 0.05% w/v SDS. The upper running buffer
was 6 the concentration of the lower running buffer and beta-
mercaptoethanol was added before use at a ﬁnal concentration
of 0.12%v/v. Electrophoretic separation was performed in two
stages. Sample entry into the stacking gel was run at 10 mA for
40 min, the remainder of the electrophoresis was carried out at
140 V (constant voltage) for 21.3 h. Throughout the electropho-
resis, the apparatus was kept in a cold room at 4C. Following
electrophoresis, the different MHC isoforms were detected by
silver staining43 and analysed by semi-quantitative densitometry
(Bio-Rad, FluorS) according to the manufacturer’s instructions.
Statistical analysis
All data are reported as means standard error of the mean
(S.E.M.). Comparisons were performed using the independent
samples t-test between two groups, or analysis of variance (ANOVA)
between multiple groups. Appropriate post-hoc tests were used to
test for signiﬁcance, with signiﬁcance accepted as P< 0.05.
Results
Clenbuterol administration increases rodent bodyweight, growth
rate and quadriceps muscle mass
Subcutaneous administration of clenbuterol at a dosage of
1.5 mg/kg/day resulted in a 35% elevation in weight gain following
14daysof treatment (P¼<0.001) (Fig.1), compared to saline control
treated animals. Analysis of growth rate (derived from daily weight
data) revealed an initial reduction in weight during the ﬁrst three
doses of clenbuterol followed by an increase in growth rate (g/day
gained) from dose 4 onwards (P¼<0.001) compared with saline
treated controls (Table I). On evisceration, treated animals had
visibly reduced adipose deposits and larger, more deﬁned skeletalmusculature. In addition to total bodyweight, quadriceps mass was
elevated (þ40%) following clenbuterol treatment (6.52 g 0.21)
compared with saline treated controls (4.64 g 0.21), (P¼<0.001).
Statistical signiﬁcance was maintained when quadriceps mass was
normalised to total bodyweight (P¼ 0.020).
MHC isoform protein expressionwas used as an index of muscle
function. Our analysis showed that the rat quadriceps muscle is
predominantly composed of ‘‘fast twitch’’ MHC, with a composition
of 4.85% type I, 7.25% type IIA, 22.34% type IIX and 66.55% type IIB
(Fig. 2). Clenbuterol administration exhibited an apparent 16%
increase in total MHC protein expression relative to total protein
(data not presented), although there was no change in the
composition of the different MHC isoforms (Table I).
MNX surgery results in OA-like lesions, weight bearing
perturbations and alters the MHC composition of the
quadriceps muscle
MNX surgery was associated with a reduction in weight gain
(16.921.12%) compared with those animals undergoing the sham
Table III
The effects of MNX and treatment regime on joint histopathology
Parameter Saline MNX Clenbuterol MNX P value
Proteoglycan/chondrocyte loss (TIB) 1.90 0.18 2.10 0.23 0.491
Erosion/ulceration (TIB) 1.10 0.35 1.30 0.34 0.663
Subchondral degeneration (TIB) 0.20 0.13 0.50 0.27 0.485
Proteoglycan/chondrocyte loss (FEM) 0.40 0.22 0.80 0.25 0.202
Erosion/ulceration (FEM) 0 0 0 0 –
Subchondral degeneration (FEM) 0 0 0 0 –
Total pathology 3.20 0.59 3.90 0.73 0.398
Of those animals subjected to MNX surgery (Saline MNX (n¼ 10), Clen MNX
(n¼ 10)), histopathological examination was performed by microscopically evalu-
ating toluidine stained step coronal joint sections for evidence of OA on both the TIB
and FEM condyles. Data are mean pathology score S.E.M. P values refer to differ-
ences in OA severity between saline and clenbuterol pre-treated subjects as
determined by Mann–Whitney analysis.
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period (Table II). Of those animals subjected to MNX surgery,
histopathological examination of the ipsilateral limbs revealed
evidence of OA-like lesions, predominantly localised at the TIB
condyle. Microscopically, meniscectomised tibias presented with
proteoglycan and chondrocyte loss, erosion and ulceration of the
articular surface, but limited evidence of subchondral degenera-
tion. FEM condyles showed evidence of proteoglycan loss; however
this was less severe than that noted on the respective TIB condyles.
No FEM erosion, ulceration or subchondral degenerationwas noted
within the experimental timeframe (Table III). sham operated
control animals were free from OA 21 days post surgery.
Surgery was also associated with a reduced quadriceps mass
relative to bodyweight (1.60 0.05) compared with those animals
that underwent a sham procedure (1.69 0.02) at the end of the
study although this did not reach statistical signiﬁcance (P¼ 0.154).
Electrophoretic examination of the quadriceps muscles at 21 days
post surgery was performed to examine changes in the MHC
expression proﬁle (Fig. 2). Compared to the sham control animals,
MNX operated (saline pre-treated) animals exhibited an apparent
115% increase in the protein expression of the slow twitch MHC I
(P¼ 0.08), numerically in lieu of fast twitch MHC IIB (Table II).
Incapacitance assessment (as a marker of weight bearing/
behavioural pain) demonstrated a 50:50 load distribution betweenFig. 3. The effects of MNX surgery and treatment regime on weight bearing. The effect of
clenbuterol (black line; n¼ 10) pre-treated meniscectomised animals. Two days prior to in
Animals were pre-treated from day 1 through day 14 and surgery performed on day 15. Prior
distribution was assessed using an incapacitance meter (Linton, UK) and data expressed asthe hind limbs prior to surgery (Fig. 3). Following MNX surgery,
signiﬁcantly less weight was placed on the ipsilateral limb (day 14
vs day 21, day 28, day 35; P¼< 0.001). Weight distribution
between the hind limbs of the MNX treated animals resolved over
a period of 14 days post surgery, although equal distribution was
not achieved within the experimental timeframe.
Clenbuterol-induced muscle hypertrophy is unable to modulate the
severity of disease
Animals pre-treated with clenbuterol prior to MNXwere unable
to maintain the previously noted increase in quadriceps mass
relative to bodyweight (1.70 0.02) compared to saline pre-treated
meniscectomised subjects (1.60 0.05) at the end of the study
(P¼ 0.154). The characteristic reduction in bodyweight gain
following MNX was suppressed in response to clenbuterol pre-
treatment, leading to similar weight gain to those animals under-
going the sham control procedure (clenbuterol MNX: 20.161.11%,
sham control 24.03 0.98%). Electrophoretic analysis of MHC iso-
forms demonstrated that clenbuterol pre-treatment prior to MNX
suppressed the increase in MHC I protein, which was previously
associated with MNX surgery, and numerically, maintained the
MHC IIB complement (Table II). However, 14 days pre-treatment
with the b2-agonist clenbuterol had no signiﬁcant effect on TIB or
FEM pathology 21 days post MNX compared to those animals pre-
treated for 14 days with saline. Microscopically, the severity of
proteoglycan and chondrocyte loss, ulceration and subchondral
degeneration observed post surgery remained unaffected from the
pre-treatment with clenbuterol (Table III).
Discussion
This is the ﬁrst study to report the role of the quadriceps muscle,
and the effects of induced skeletal muscle hypertrophy on the
severity of joint pathology in an animal model of OA. Here, we
observed a trend towards increased slow, MHC I protein in the
quadriceps during the induction of OA-like cartilage lesions in the
rat MNX model of OA, as determined by MHC protein expression.
We also observed that the gross increase in the quadriceps muscle
induced by the b2 adrenergic agonist, clenbuterol, could notMNX surgery on weight bearing was assessed in both saline (grey line; n¼ 10) and
clusion in the study, animals were acclimatised to the incapacitance equipment (d-2).
to surgery and during the 21-day development phase immediately post surgery, weight
the percentage of total weight distributed to the operated limb S.E.M.
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pain in this model.
The use of clenbuterol to induce skeletal muscle hypertrophy
and promote lipolysis is well characterised across multiple
species44. Here, following 2 weeks of clenbuterol treatment we
attained a signiﬁcant increase in the quadriceps muscle mass
(þ40%). However, at the study endpoint, the hypertrophic effect of
clenbuterol was no longer apparent in the pre-treated animals,
which presented with comparable quadriceps mass to bodyweight
ratios. To determine muscle ﬁbre composition of the quadriceps,
we monitored MHC protein expression. Of interest we found that
although no changes to theMHC protein compositionwere noted in
response to clenbuterol prior to surgery, subtle effects of clenbu-
terol on MHC protein expression were observed in the period post
surgery where clenbuterol suppressed the trend towards an MNX
surgery-induced increase in MHC I. Although we only noted a trend
association between pre-treatment with clenbuterol and suppres-
sion of the increase in MHC I protein observed post surgery
(P¼ 0.081), this is supported by several studies that report the slow
to fast ﬁbre inducing effects of clenbuterol in rodents44. The fact
that we did not observe these changes in the pre-treatment period
may be due to the length of drug exposure and/or the muscle
studied. The latter may be related to the natural distribution of
MHC protein isoforms within the quadriceps muscle which
comprises over 85% fast MHC IIX/MHC IIB, and less than 15% slower
MHC I/MHC IIA. Such a high baseline complement of fast MHC is
likely to reduce the impact of a drug such as clenbuterol with
regards to its effect in inducing slow to fast ﬁbre type transitions.
Previous studies noting such changes were often conducted over
a longer timeframe and tended to study the slow twitch soleus
muscle, which is particularly susceptible to ﬁbre type shifts.
As previously noted, MNX surgery was associated with a trend
towards increased MHC I, indicative of a switch towards a slower
more oxidative and fatigue resistant muscle type, more commonly
associated with postural, anti-gravity muscles45. Such changes in
muscle ﬁbre type following MNX may have important implications
for rehabilitation, in particular the type of muscle strengthening
program recommended. One possible reason for this change in
MHC composition in response to MNX surgery might be that it is
a physiological attempt to increase stability of the operated joint by
increasing the complement of fatigue resistant, slow muscle ﬁbres
that surround it. A further possibility is that surgery-induced
changes in weight bearing led to disuse atrophy of fast MHC IIB
ﬁbres, resulting in an increase in the relative proportion of slower
MHC I ﬁbres as noted previously46. We must stress however, that
only mild changes to weight bearing were noted (w4%) and it is
unclear whether such modest perturbations are capable of
inducing changes to the relative distribution of MHC.
A number of previous studies suggest that modulating muscle
function through exercise may have an impact on the development
and severity of OA in humans; therefore we must consider why no
effect was noted in this experimental model. The experimental
approach chosen in the present study was to dose with clenbuterol
for up to 2 weeks prior to surgical induction of OA, but to stop
administration immediately after surgery. This approach avoided
any potential confounding factors of direct clenbuterol action at
the joint or direct cardiovascular effects and in our opinion allowed
us to better mimic the physiological impact of a hypertrophic
quadriceps muscle on OA severity. However, although clenbuterol
resulted in marked increases in quadriceps mass during the pre-
treatment period, this effect was not maintained throughout the
time course of the study and may explain the lack of effect on OA
severity reported in the study. Another possibility might be the
agent of choice we used in this study to induce muscle hyper-
trophy. Although clenbuterol is effective in this regard, it also leadsto an overall increase in animal bodyweight due to the induction of
lean mass, a concurrent decline in fat mass and the relatively high
mass of skeletal muscle compared to that of adipose tissue47,48. It is
well known that weight is a risk factor for knee OA49. Moreover,
bodyweight has been associated with the severity of OA in the
Dunkin Hartley guinea pig where a 28% reduction in bodyweight
led to a marked 40% decrease in OA severity50. By inference, it is
therefore possible that this increased bodyweight in our clenbu-
terol treated animals compared to the control animals, at the time
of induction, may have negated any potential beneﬁcial effect of
a strengthened quadriceps, and thus explains the lack of positive
modulation noted during this study. A further possibility is that
muscle mass is not the sole or the major determinant with regards
to the role of muscles in OA. Instead, it is likely that it is the
coordinate modulation of several muscle parameters such as
muscle ﬁbre type composition and size of motor units recruited
during exercise that together with mass, are key in eliciting an
impact on OA pathology.
In addition it is also important to note that clenbuterol has
greater hypertrophic effects on slow twitchmuscles comparedwith
faster twitch muscles35,36. In the intact knee, agonist force is
generated by the quadriceps muscle in tandem with antagonist
force generation by the hamstrings producing joint stability51. If
one considers the quadriceps/hamstrings balance (Q/H ratio) and
that anabolic steroid-induced hypertrophy might elicit a greater
strength increases in leg ﬂexion over leg extension52, it is
possible that clenbuterol administration induced skeletal muscle
hypertrophy disproportionately across the various muscles
surrounding the knee joint, disrupting the ﬁne balance of agonist
and antagonist forces, leading to decreased joint stability. This
could have a detrimental effect on the formation of joint pathology
in a similar way to that observed inmanwith joint instability due to
joint mal-alignments53.
In summary, these ﬁndings suggest that clenbuterol-induced
gross increases in skeletal musculature do not modulate the
severity of OA in the rodent MNX model. We propose that animal
models of OA that better mimic the human condition in terms of
initiation and progression rates, and the use of pharmacological
agents that more selectively target the Q/H ratio without additional
weight gain, may provide a more suitable platform on which to
observe subtle changes in disease progression brought about
through modulating skeletal muscle function.
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